An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Did you know that one classical dance form from India is lovingly called the “Ballad…
Arunachal Pradesh Foundation Day 2026 will be celebrated on 20 February to mark the formation…
On 20 February 2026, India captain Harmanpreet Kaur created history by becoming the most-capped player…
In a landmark corporate milestone, Amazon has officially surpassed Walmart to become the world’s largest…
India has taken a major step towards strengthening global food security as the Food Corporation…
Reliance Industries Chairman Mukesh Ambani announced a massive ₹10 trillion investment in artificial intelligence over…